{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:43:30Z","timestamp":1791193410172,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1124\/jpet.111.191247","type":"journal-article","created":{"date-parts":[[2012,3,15]],"date-time":"2012-03-15T00:19:10Z","timestamp":1331770750000},"page":"725-734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Attenuation of Cisplatin-Induced Renal Injury by Inhibition of Soluble Epoxide Hydrolase Involves Nuclear Factor \u03baB Signaling"],"prefix":"10.1016","volume":"341","author":[{"given":"Yingmei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather K.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayo","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Micheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Markova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna L.","family":"Kroetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.111.191247_bib1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3132\/dvdr.2008.021","article-title":"Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study","volume":"5","author":"Burdon","year":"2008","journal-title":"Diab Vasc Dis Res"},{"key":"10.1124\/jpet.111.191247_bib2","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1073\/pnas.261710799","article-title":"Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation","volume":"99","author":"Davis","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/jpet.111.191247_bib3","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1046\/j.1523-1755.2001.00043.x","article-title":"Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury","volume":"60","author":"Deng","year":"2001","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.111.191247_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/jpet.107.119792","article-title":"Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1\u03b2, IL-18, IL-6, and neutrophil infiltration in the kidney","volume":"322","author":"Faubel","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.191247_bib5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/FPC.0b013e3283349ec9","article-title":"Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes","volume":"20","author":"Fava","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/jpet.111.191247_bib6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1124\/jpet.108.142398","article-title":"Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation","volume":"327","author":"Fife","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.191247_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.RES.88.1.44","article-title":"Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries","volume":"88","author":"Fleming","year":"2001","journal-title":"Circ Res"},{"key":"10.1124\/jpet.111.191247_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/01.CIR.0000109487.46725.02","article-title":"Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study","volume":"109","author":"Fornage","year":"2004","journal-title":"Circulation"},{"key":"10.1124\/jpet.111.191247_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.tox.2006.10.025","article-title":"Parthenolide reduces cisplatin-induced renal damage","volume":"230","author":"Francescato","year":"2007","journal-title":"Toxicology"},{"key":"10.1124\/jpet.111.191247_bib10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/hy0202.103788","article-title":"Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension","volume":"39","author":"Imig","year":"2002","journal-title":"Hypertension"},{"key":"10.1124\/jpet.111.191247_bib11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/01.HYP.0000176237.74820.75","article-title":"An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension","volume":"46","author":"Imig","year":"2005","journal-title":"Hypertension"},{"key":"10.1124\/jpet.111.191247_bib12","series-title":"Guide for the Care and Use of Laboratory Animals","year":"1996"},{"key":"10.1124\/jpet.111.191247_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1074-7613(00)80535-X","article-title":"The death domain kinase RIP mediates the TNF-induced NF-\u03baB signal","volume":"8","author":"Kelliher","year":"1998","journal-title":"Immunity"},{"key":"10.1124\/jpet.111.191247_bib14","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1046\/j.1523-1755.1999.00629.x","article-title":"Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody","volume":"56","author":"Kelly","year":"1999","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.111.191247_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00041433-200206000-00007","article-title":"Cytochrome P450 pathways of arachidonic acid metabolism","volume":"13","author":"Kroetz","year":"2002","journal-title":"Curr Opin Lipidol"},{"key":"10.1124\/jpet.111.191247_bib16","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/hmg\/ddl085","article-title":"Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study","volume":"15","author":"Lee","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.111.191247_bib17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1161\/HYPERTENSIONAHA.110.161695","article-title":"Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans","volume":"57","author":"Lee","year":"2011","journal-title":"Hypertension"},{"key":"10.1124\/jpet.111.191247_bib18","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1093\/ndt\/gfl194","article-title":"Rosiglitazone ameliorates cisplatin-induced renal injury in mice","volume":"21","author":"Lee","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.111.191247_bib19","doi-asserted-by":"crossref","first-page":"F469","DOI":"10.1152\/ajprenal.00038.2005","article-title":"Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF","volume":"289","author":"Li","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.111.191247_bib20","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bcp.2009.10.025","article-title":"Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model","volume":"79","author":"Liu","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.111.191247_bib21","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1124\/jpet.110.167544","article-title":"Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis","volume":"334","author":"Luo","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.191247_bib22","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1074\/jbc.M608057200","article-title":"Ephx2 gene-disrupted mice","volume":"282","author":"Luria","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.111.191247_bib23","doi-asserted-by":"crossref","first-page":"F740","DOI":"10.1152\/ajprenal.00098.2009","article-title":"Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension","volume":"297","author":"Manhiani","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.111.191247_bib24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/ng.129","article-title":"Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease","volume":"40","author":"Monti","year":"2008","journal-title":"Nat Genet"},{"key":"10.1124\/jpet.111.191247_bib25","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1194\/jlr.D200018-JLR200","article-title":"The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS\/MS","volume":"43","author":"Newman","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1124\/jpet.111.191247_bib26","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1124\/dmd.106.013839","article-title":"Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor \u03b1","volume":"35","author":"Ng","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.111.191247_bib27","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1126\/science.285.5431.1276","article-title":"Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids","volume":"285","author":"Node","year":"1999","journal-title":"Science"},{"key":"10.1124\/jpet.111.191247_bib28","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","article-title":"Cisplatin nephrotoxicity: mechanisms and renoprotective strategies","volume":"73","author":"Pabla","year":"2008","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.111.191247_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10565-008-9071-0","article-title":"Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase","volume":"25","author":"Parrish","year":"2009","journal-title":"Cell Biol Toxicol"},{"key":"10.1124\/jpet.111.191247_bib30","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1172\/JCI200215606","article-title":"TNF-\u03b1 mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity","volume":"110","author":"Ramesh","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.111.191247_bib31","doi-asserted-by":"crossref","first-page":"F610","DOI":"10.1152\/ajprenal.00101.2003","article-title":"TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure","volume":"285","author":"Ramesh","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.111.191247_bib32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1523-1755.2004.00413.x","article-title":"Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-\u03b1","volume":"65","author":"Ramesh","year":"2004","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.111.191247_bib33","doi-asserted-by":"crossref","first-page":"21151","DOI":"10.1074\/jbc.271.35.21151","article-title":"Human tumor necrosis factor receptor p75\/80 (CD120b) gene structure and promoter characterization","volume":"271","author":"Santee","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.111.191247_bib34","doi-asserted-by":"crossref","first-page":"9772","DOI":"10.1073\/pnas.0503279102","article-title":"Soluble epoxide hydrolase is a therapeutic target for acute inflammation","volume":"102","author":"Schmelzer","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/jpet.111.191247_bib35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.RES.0000237390.92932.37","article-title":"Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function","volume":"99","author":"Seubert","year":"2006","journal-title":"Circ Res"},{"key":"10.1124\/jpet.111.191247_bib36","doi-asserted-by":"crossref","first-page":"H795","DOI":"10.1152\/ajpheart.00543.2009","article-title":"Soluble epoxide hydrolase inhibition modulates vascular remodeling","volume":"298","author":"Simpkins","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/jpet.111.191247_bib37","doi-asserted-by":"crossref","first-page":"40504","DOI":"10.1074\/jbc.M008106200","article-title":"Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation","volume":"275","author":"Sinal","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.111.191247_bib38","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1073\/pnas.0409591102","article-title":"Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor","volume":"102","author":"Smith","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/jpet.111.191247_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0163-7827(03)00049-3","article-title":"Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function","volume":"43","author":"Spector","year":"2004","journal-title":"Prog Lipid Res"},{"key":"10.1124\/jpet.111.191247_bib40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1523-1755.2003.00709.x","article-title":"Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death","volume":"63","author":"Tsuruya","year":"2003","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.111.191247_bib41","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11883-010-0108-5","article-title":"Soluble epoxide hydrolase in atherosclerosis","volume":"12","author":"Wang","year":"2010","journal-title":"Curr Atheroscl Rep"},{"key":"10.1124\/jpet.111.191247_bib42","doi-asserted-by":"crossref","first-page":"H142","DOI":"10.1152\/ajpheart.00783.2006","article-title":"Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-\u03b1 via MAPK and PI3K\/Akt signaling pathways","volume":"293","author":"Yang","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/jpet.111.191247_bib43","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1124\/jpet.107.119651","article-title":"Characterization of 14,15-epoxyeicosatrienoyl-sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: use for studies of metabolism and ligand binding","volume":"321","author":"Yang","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.191247_bib44","doi-asserted-by":"crossref","first-page":"17795","DOI":"10.1074\/jbc.272.28.17795","article-title":"Lipopolysaccharide induction of the tumor necrosis factor-\u03b1 promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-\u03baB transcription factors","volume":"272","author":"Yao","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.111.191247_bib45","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0026-895X(24)26512-3","article-title":"Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney","volume":"57","author":"Yu","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.111.191247_bib46","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1124\/jpet.105.098558","article-title":"Induction of renal cytochrome P450 arachidonic acid epoxygenase activity by dietary \u03b3-linolenic acid","volume":"317","author":"Yu","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.191247_bib47","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/01.RES.87.11.992","article-title":"Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids","volume":"87","author":"Yu","year":"2000","journal-title":"Circ Res"},{"key":"10.1124\/jpet.111.191247_bib48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.ki.5002242","article-title":"Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-\u03b1 produced by renal parenchymal cells","volume":"72","author":"Zhang","year":"2007","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.111.191247_bib49","first-page":"1244","article-title":"Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage","volume":"15","author":"Zhao","year":"2004","journal-title":"J Am Soc Nephrol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524182365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524182365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.111.191247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:06:32Z","timestamp":1739984792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524182365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0022356524182365"],"URL":"https:\/\/doi.org\/10.1124\/jpet.111.191247","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attenuation of Cisplatin-Induced Renal Injury by Inhibition of Soluble Epoxide Hydrolase Involves Nuclear Factor \u03baB Signaling","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.111.191247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}